| 2026-08-13 | Press release | Maze Therapeutics Announces Appointments to Its Board of Directors |
| 2026-08-11 | Press release | Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights |
| 2026-06-12 | Presentation | Maze Corporate Presentation |
| 2026-05-27 | Press release | Maze Therapeutics to Participate in Two Upcoming Investor Conferences |
| 2026-05-12 | Press release | Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights |
| 2026-04-22 | Press release | Maze Therapeutics Announces $150 Million Registered Offering |
| 2026-03-25 | Press release | Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical |
| 2026-03-25 | Press release | Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights |
| 2026-02-25 | Press release | Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference |
| 2026-01-05 | Press release | Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-11-06 | Press release | Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights |
| 2025-11-06 | Press release | Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney We |
| 2025-09-11 | Press release | Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanis |
| 2025-03-31 | Press release | Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights |
| 2025-02-07 | Press release | Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for A |
| 2024-10-25 | Press release | Maze Therapeutics Reports Positive First-in-Human Data from Phase 1 Healthy Volunteer Clinical Trial Evaluating MZE829 a |
| 2024-10-15 | Press release | Maze Therapeutics to Present New Data Supporting Advancement of MZE829 and MZE782 Clinical Development at American Socie |
| 2024-05-10 | Press release | Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Ther |
| 2023-11-04 | Press release | Maze Therapeutics Highlights New Preclinical Data Supporting Advancement of APOL1 Inhibitor Candidate Toward Clinical Ev |
| 2023-05-01 | Press release | Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Th |
| 2023-03-22 | Press release | Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease |
| 2023-02-27 | Press release | Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Tre |
| 2022-12-15 | Press release | Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment f |
| 2022-11-04 | Press release | Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic |
| 2022-08-31 | Press release | Maze Therapeutics Announces FDA Orphan Drug Designation Granted to MZE001 for the Treatment of Pompe Disease |
| 2022-02-17 | Press release | Maze Therapeutics Announces Phase 1 Trial Initiation Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease |
| 2022-02-10 | Press release | Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Dise |
| 2022-01-31 | Press release | Maze Therapeutics to Present Preclinical Data Highlighting MZE001 as a Potential Treatment for Pompe Disease at 2022 WOR |
| 2020-12-07 | Press release | BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Dis |
| Press release | Maze Therapeutics Initiates Phase 1 First-in-Human Trial Evaluating MZE782 as a Potential Treatment for Chronic Kidney D |
| Press release | Maze Therapeutics Announces Publication of Research Demonstrating Newly Identified Variant for APOL1 Kidney Disease is A |
| Press release | Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a |